Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog

References

• BEAUMONT, K. C., CAUSEY, A. G., COATES, P. E. and SMITH, D. A., 1996, Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man. Xenobiotica, 26, 459–471.
   PubMed Web of Science ®Google Scholar
• DAVIES, A. J., HARINDRA, V., McEwAN, A. and GHOSE, R. R., 1989, Cardiotoxic effect with convulsions in terfenadine over dose. British Medical Journal, 298, 325.
   PubMed Web of Science ®Google Scholar
• DAVIS, S. A., 1998, The preclinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Human and Experimental Toxicology, 17, 677–680.
   PubMedGoogle Scholar
• GARTEIZ, D. A., HOOK, R. H., WALKER, B. J. and OKERHOLM, R. A., 1982, Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim.-Forsch.1Drug Research, 32, 1185–1190.
   Google Scholar
• GRALINSKI, M. R., 2000, The assessment of potential for QT interval prolongation with new pharmaceuticals. Impact on drug development. Journal of Pharmacology and Toxicological Methods, 43, 91–99.
   PubMed Web of Science ®Google Scholar
• GRAS, J. and LLENAS, J., 1999, Effects of H1 antihistamines on animal models of QTc prolongation. Drug Safety, 21, 39–44.
   PubMedGoogle Scholar
• HALLEN, B., GABREILSSON, J., NYAMBATI, S., JOHANSSON, A., LARSSON, E. and GUILBAUD, O., 1995, Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. Pharmacology and Toxic olology, 76, 171-1 77.
   Google Scholar
• HALLEN, B., GABREILSSON, J., PALMER, L. and EKSTROM, B., 1993, Pharmacokinetics of R(+) terodiline given intravenously and orally to healthy volunteers. Pharmacology and Toxicolology, 73, 153–158.
   PubMedGoogle Scholar
• HALLEN, B., GRALLS, M., BROTELL, H. and STROMBERG, S., 1990, Pharmacokinetics of terodiline and a major metabolite in dogs with a correlation to a pharmacodynamic effect. Pharmacology and Toxicology, 66, 373–381.
   PubMedGoogle Scholar
• HARTIGAN-GO, K., BATEMAN, D. N., DALY, A. K. and THOMAS, S. H. L., 1996, Stereoselective cardiotoxic effects of terodiline. Clinical Pharmacology and Therapeutics, 60, 89–98.
   Google Scholar
• IMAMURA, H., FURUKAWA, Y., NAKANO, H., KAsAmA, M., HOYANO, Y. and CHIBA, S., 1995, Selective inhibition by a class III anti-arrhythmic agent, E4031, of the negative chronotropic response to parasympathetic stimulation in anesthetized dogs. Journal of Pharmacology and Experimental Therapeutics, 276, 467–472.
   Google Scholar
• KARLEN, B., ANDERSSON, K. E., EKMAN, G. and ULMSTEN, U., 1982, Pharmacokinetics of terodiline in human volunteers. European Journal of Clinical Pharmacology, 23, 267–270.
   PubMed Web of Science ®Google Scholar
• KASAMA, M., FURUKAWA, Y., Ouucin, T., HOYANO, Y. and CHIBA, S., 1998, Effects of low temperature on the chronotropic and inotropic responses to zatebradine, E-4031 and verapamil in isolated perfused dog atria. Japanese Journal of Pharmacology, 78, 493–499.
   PubMedGoogle Scholar
• KATOH, H., OGAWA, S., FURUNO, I., SATO, Y., YOH, S., SAEKI, K. and NAKAMURA, Y., 1990, Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re-entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. Journal of Pharmacology and Experimental Therapeutks, 253, 1077–1082.
   PubMedGoogle Scholar
• LEISHMAN, D. J., DOUTHWAITE, M., KIDD, T., MEANER, P., WALKER, D. K., WEST, H. and WALLIS, R. M., 2000a, Effects of E4031, cisapide, terfenadine and terodiline on monophasic action potential duration (MAPD) and incidence of Torsade des pointes (TdP) in the dog. British Journal of Pharmacology, 133, 131.
   Google Scholar
• LEISHMAN, D. J., HELLIWELL, R., WAKERELL, J. and WALLis, R. M., 2000b, Effects of E4031, cisapide, terfenadine and terodiline on cardiac repolarisation in canine Purkinje fibre and HERG channels expressed in HEK293 cells. British Journal of Pharmacology, 133, 130.
   Google Scholar
• MACCONNELL, T. J. and STANNERS, A. J., 1991, Torsades de pointes complicating treatment with terfenadine. British Medical journal, 302, 1469.
   PubMed Web of Science ®Google Scholar
• MCTAVISN, D., GoA, K. L. and FERRILL, M., 1990, Terfenadine: an updated review of its pharmacological properties and therapeutic efficacy. Drugs, 39, 552–574.
   PubMedGoogle Scholar
• MICHALETS, E. L. and WILLIAMS, C. H., 2000, Drug interactions of cisapride. Clinical Pharmacokinetics, 39, 49–75.
   PubMed Web of Science ®Google Scholar
• MICHIELS, M., MONBALIU, J., HENDRIKS, R., GEERTS, R., WOESTENBORGHS, R. and HEYKANTS, J., 1987, Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. Arzneim.-Forsch.1Drug Research, 37, 1159–1167.
   Google Scholar
• MOHAMMAD, S., Znou, Z., GONNG, Q. and JANUARY, C. T., 1997, Blockade of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Amerk an journal of Pharmacology, 273, 2538–2538.
   Google Scholar
• MONAHAN, B. P., FERGUSON, C. L., KILLEAVY, E. S., LLOYD, B. K., TROY, J. and CANTILENA, L. R., 1990, Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association, 264, 2788–2790.
   PubMed Web of Science ®Google Scholar
• °BACH, R. S., BAXTER, J. G., LISTON, T. E., SILBER, B. M., JONES, B. C., MACINTYRE, F., RANCE, D. J. and WASTALL, P., 1997, The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics, 283, 46–58.
   PubMedGoogle Scholar
• OHTANI, H., KOTAKI, H., SAWADA, Y. and IGA, T., 1997, A comparative pharmacokinetic—pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. Journal of Pharmacokinetics and Pharmacology, 49, 458–462.
   Google Scholar
• SALATA, J. I., JURKIEWICZ, N. K., WALLACE, A. A., STUPIENSKI, R. F., GUINOSSO, P. J. and LYNCH, J. J., 1995, Cardiac electrophysiological actions of the histamine Hl-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circulation Research, 76, 110–119.
   PubMed Web of Science ®Google Scholar
• SJOQVIST, F., 1985, Blood binding and drug monitoring. In Tillement, J. P. and Lindenlaub, E. (eds), Protein Binding and Drug Transport (Stuttgart F. K. Schattauer), pp. 429-441.
   Google Scholar
• SMITH, D. A., 1997, Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica, 27, 513–525.
   PubMed Web of Science ®Google Scholar
• VAUGHAN WILLIAMS, E. M., 1970, Classification of anti-arrhythmic drugs. In E. Sandoe and E. Flenstead-Jenson (eds), Symposium on Cardiac Arrhythmias (Sodertalte, Sweden: AB Astra), pp. 449–472.
   Google Scholar
• VEEREMAN-WAUTERS, G., MONBALIU, J., MEULDERMANS, W., WOESTENBORGHS, R., VERLINDEN, M., HEYKANTES, J. and RUDOLPH, C. D., 1991, Study of the placental transfer of cisapride in sheep: Plasma levels in the pregnant ewe, the fetus and the lamb. Drug Metabolism and Disposition, 19, 168–172.
   PubMedGoogle Scholar
• WOOSLEY, R. L., CHEN, Y., FREIMAN, J. P. and Gluts, R. A., 1993, Mechanism of the cardiotoxic actions of terfenadine. Journal of the American Medical Association, 269, 1532–1536.
   PubMed Web of Science ®Google Scholar
• WRIGHT, A., RAVAL, P., EDEN, R. J. and OWEN, D. A. A., 1987, Histamine Hi-receptor antagonist activity assessed in conscious dogs. Journal of Pharmacological Methods, 18, 123-1 29.
   Google Scholar